Treatment of ANCA-associated vasculitis, Where to go?

Clinical Reviews in Allergy and Immunology

Volumn 43, Issue 3, 2012, Pages 242-248

  Kallenberg, Cees G M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

ANCA associated vasculitis; Granulomatosis with polyangiitis; Microscopic polyangiitis; Rituximab; Treatment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY;

ANCA ASSOCIATED VASCULITIS; ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; MORBIDITY; PLASMAPHERESIS; RECURRENCE FREE SURVIVAL; RELAPSE; REMISSION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; AZATHIOPRINE; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84871663775     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-012-8325-z     Document Type: Article

References (33)

1. Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187-192 (Pubitemid 24065492)
2. Walton EW (1958) Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 2(5091):265-270
3. Fauci AS, Katz P, Haynes BF, Wolff SM (1979) Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 301:235-238 (Pubitemid 9234482)
4. Hoffman GS, Kerr GS, Leavitt RY et al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488-498
5. Talar-Williams C, Hijazi YM, Walther MM et al (1996) Cyclophosphamide- induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124:477-484 (Pubitemid 26070112)
6. De Groot K, Harper L, Jayne DR (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-Associated vasculitis: a randomized trial. Ann Intern Med 150:670-680
7. Harper L, Morgan MD, Walsh M et al (2011) Pulse versus daily oral cyclophosphamide for induction of remission in ANCAassociated vasculitis: long-Term follow-up. Ann Rheum Dis. Nov 29, [Epub ahead of print]
8. JoyMS, Hogan SL, Jennette JC, Falk RJ, Nachman PH (2005) A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 20:2725-2732 (Pubitemid 41672272)
9. Silva F, Specks U, Kalra S, Hogan MC, Leung N, Sethi S, Fervenza FC (2010) Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement -A prospective, open-label pilot trial. Clin J Am Soc Nephrol 5:445-453
10. Stassen PM, Tervaert JW, Stegeman CA (2007) Induction of remission in active anti-neutrophil cytoplasmic antibodyassociated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 66:798-802 (Pubitemid 46846700)
11. Han F, Liu G, Zhang X et al (2011) Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis. Am J Nephrol 33:185-192
12. De Groot K, Rasmussen N, Bacon PA et al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 52:2461-2469 (Pubitemid 41117433)
13. Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-Associated vasculitis. N Engl J Med 363:221-232
14. Jones RB, Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-Associated renal vasculitis. N Engl J Med 363:211-220
15. Specks U, Stone JH, for the RAVE-ITN Research Group (2011) Long-Term efficacy and safety results of the RAVE trial. Clin Exp Immunol 164(suppl 1):65
16. Rutgers A, Kallenberg CG (2011) Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis. Curr Opin Rheumatol 24:245-251
17. Guillevin L, Mahr A (2011) Rituximab to treat ANCA-Associated vasculitis. Rev Med Interne 32:591-593
18. Holle JU, Gross WL (2011) Rituximab in AAV: when and how to use it. Nat Rev Rheumatol 7:566-567
19. Guerry MJ, Brogan P, Bruce IN et al (2012) Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibodyassociated vasculitis. Rheumatology (Oxford) 51:634-643
20. Jayne DR, Gaskin G, Rasmussen N et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18:2180-2188 (Pubitemid 47041083)
21. Mukhtyar C, Guillevin L, Cid MC et al (2009) European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68:310-317
22. Jayne D, Rasmussen N, Andrassy K et al (2003) European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36-44 (Pubitemid 36765101)
23. Pagnoux C, Mahr A, Hamidou MA et al (2008) Azathioprine or methotrexate maintenance for ANCA-Associated vasculitis. N Engl J Med 359:2790-2803
24. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, De Groot K (2002) High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 47:326-332 (Pubitemid 34627702)
25. Dooley MA, Jayne D, Ginzler EM et al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365:1886-1895
26. Hiemstra TF, Walsh M, Mahr A et al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-Associated vasculitis: a randomized controlled trial. JAMA 304:2381-2388
27. Rhee EP, Laliberte KA, Niles JL (2010) Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-Associated vasculitis. Clin J Am Soc Nephrol 5:1394-1400
28. Pagnoux C, Hogan SL, Chin H et al (2008) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibodyassociated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 58:2908-2918
29. Stegeman CA, Cohen Tervaert JW, Sluiter WJ et al (1994) Association of nasal carriage of Staphylococcus aureus and higher relapse in Wegener's granulomatosis. Ann Intern Med 120:12-17 (Pubitemid 24011495)
30. Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C, Coste J, Guillevin L (2010) Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford) 49:2181-2190
31. Walsh M, Flossmann O, Berden A et al (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-Associated vasculitis. Arthritis Rheum 64:542-548
32. Tadema H, Heeringa P, Kallenberg CG (2011) Bacterial infections in Wegener's granulomatosis: mechanisms potentially involved in autoimmune pathogenesis. Curr Opin Rheumatol 23:366-371
33. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CGM (1996) Trimethoprim-sulfamethoxazole (co-Trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Eng J Med 335:16-20 (Pubitemid 26230808)